Collectively, Flatiron’s presentations at this year’s American Society of Clinical Oncology Annual Meeting (ASCO20) display the broad impact of EHR-derived real-world evidence (RWE) across the oncology therapeutic lifecycle: from discovery through development and, ultimately, in support of patient care.
Highlights include the exploration of genomic biomarkers and their relationship to real-world outcomes; the use of EHRs to enable prospective data collection through a novel approach to the execution of clinical trials by linking real-world clinico-genomic, imaging and outcomes data; efforts to leverage our provider network to understand barriers to clinical trial participation and apply machine learning technology to streamline patient ascertainment; and finally, the role of real-world data in understanding treatment patterns, with attention on rare populations and end-of-life care.
Flatiron’s research collaborators include partners from academia, life sciences companies and most notably for 2020, our valued community practice partners. Our research presentations span multiple applications with one specific objective in mind: to learn from the experience of every cancer patient.
Below are highlights from a series of Flatiron-authored posters. Visit the ASCO Virtual Scientific Program to see six additional posters featuring Flatiron real-world data.